Following on from information provided to NICE by the company in April 2020 the appraisal of Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1597

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
15 November 2022 Following on from information provided to NICE by the company in April 2020 the appraisal of Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
15 November 2022 Discontinued. Following on from information provided to NICE by the company in April 2020 the appraisal of Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
17 April 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia. Following a recent update from the company, NICE has decided to suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course.
17 April 2020 Suspended. Topic has been suspended
10 May 2019 In progress. Referred 13 February 2018

For further information on our processes and methods, please see our CHTE processes and methods manual